51 results
Page 2 of 3
8-K
EX-99.1
6gj43cps
13 May 21
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
j4yf3ufacw
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
67dkur j9
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
EX-99.1
7gzffmgab wzi1p1v6yj
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
uq49y65 rc3eb7nu
30 Mar 21
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
8:05am
8-K
EX-99.1
lu1y gwxj6dalne
15 Mar 21
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
8:05am
8-K
EX-99.1
jwi8q7bt2ayqt
3 Mar 21
Regulation FD Disclosure
10:05am
8-K
EX-99.1
ognphaoqd57929s
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
424B5
gquc3o0 xxtrdy29tt
20 Nov 20
Prospectus supplement for primary offering
4:23pm
8-K
EX-99.1
rx5u3 dm6tauydnxgi
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm
8-K
EX-99.1
g43 hooev8iudjiek8s
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
ob3lnxkgr3
30 Sep 20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
8:05am
8-K
EX-99.1
uxsxw4
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm